Ligand Started at Outperform by Oppenheimer on Royalty Revenue Growth
Ligand Pharmaceuticals Initiated at Outperform by Oppenheimer
Ligand Pharmaceuticals Analyst Ratings
Oppenheimer Initiates Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $135
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum?
Ligand Pharmaceuticals Executive Sells Over $1.6m in Stock
Ligand Pharmaceuticals CFO Sells Over $130k in Company Stock
Pulling Back 4.4% This Week, Ligand Pharmaceuticals' NASDAQ:LGND) One-year Decline in Earnings May Be Coming Into Investors Focus
Express News | Ligand Pharmaceuticals - Following Engagement With FDA, Co Expects to Submit an Snda for Potential Modification to Liver-Monitoring Rems
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (Sparsentan), the Only Non-Immunosuppressive Treatment That Significantly Slows Kidney Function Decline in IgA Nephropathy
Express News | Ligand Partner Travere Therapeutics Receives Full FDA Approval for Filspari® (Sparsentan), the Only Non-Immunosuppressive Treatment That Significantly Slows Kidney Function Decline in Iga Nephropathy
Travere Gains on Full FDA Approval for Kidney Drug Filspari
Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
Small-cap and Mid-cap Health Care Has Room to Rally - Roth MKM
Looking Into Ligand Pharmaceuticals's Recent Short Interest
Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings
Private Capital's Strategic Moves Highlight Ligand Pharmaceuticals in Q2 2024
Ligand Pharmaceuticals Insider Sold Shares Worth $1,797,133, According to a Recent SEC Filing
Ligand Pharmaceuticals Is Maintained at Buy by Benchmark